What is Usana Health Sciences Inc's earnings per share (EPS)?

Usana Health Sciences Inc (USNA) reported diluted earnings per share of $0.58 for fiscal year 2026. This represents a -73.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Usana Health Sciences Inc Financials

USNA

Source SEC Filings (10-K/10-Q) Updated Jan 3, 2026 Currency USD FYE January

This page shows Usana Health Sciences Inc (USNA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Cash-Backed

2.08x

For every $1 of reported earnings, Usana Health Sciences Inc generates $2.08 in operating cash flow ($22.3M OCF vs $10.8M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

44.5x

Usana Health Sciences Inc earns $44.5 in operating income for every $1 of interest expense ($37.4M vs $842K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$925.3M

YoY+8.3%

5Y CAGR-2.7%

10Y CAGR+2.6%

Usana Health Sciences Inc generated $925.3M in revenue in fiscal year 2026. This represents an increase of 8.3% from the prior year.

EBITDA

$70.0M

YoY-13.4%

5Y CAGR-15.3%

10Y CAGR-5.7%

Usana Health Sciences Inc's EBITDA was $70.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.4% from the prior year.

Net Income

$10.8M

YoY-74.4%

5Y CAGR-36.0%

10Y CAGR-18.1%

Usana Health Sciences Inc reported $10.8M in net income in fiscal year 2026. This represents a decrease of 74.4% from the prior year.

EPS (Diluted)

$0.58

YoY-73.5%

5Y CAGR-33.4%

10Y CAGR-20.2%

Usana Health Sciences Inc earned $0.58 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 73.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$8.5M

YoY-83.3%

5Y CAGR-40.1%

10Y CAGR-21.1%

Usana Health Sciences Inc generated $8.5M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 83.3% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

18M

YoY-3.2%

5Y CAGR-3.1%

10Y CAGR+2.9%

Usana Health Sciences Inc had 18M shares outstanding in fiscal year 2026. This represents a decrease of 3.2% from the prior year.

Margins & Returns

Gross Margin

78.3%

YoY-2.8pp

5Y CAGR-4.0pp

10Y CAGR-4.0pp

Usana Health Sciences Inc's gross margin was 78.3% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is down 2.8 percentage points from the prior year.

Operating Margin

4.0%

YoY-3.7pp

5Y CAGR-9.7pp

10Y CAGR-12.2pp

Usana Health Sciences Inc's operating margin was 4.0% in fiscal year 2026, reflecting core business profitability. This is down 3.7 percentage points from the prior year.

Net Margin

1.2%

YoY-3.8pp

5Y CAGR-8.3pp

10Y CAGR-9.8pp

Usana Health Sciences Inc's net profit margin was 1.2% in fiscal year 2026, showing the share of revenue converted to profit. This is down 3.8 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$10.7M

YoY-7.6%

5Y CAGR+0.8%

10Y CAGR+7.7%

Usana Health Sciences Inc invested $10.7M in research and development in fiscal year 2026. This represents a decrease of 7.6% from the prior year.

Share Buybacks

$27.5M

YoY+191.3%

5Y CAGR-28.8%

10Y CAGR+4.3%

Usana Health Sciences Inc spent $27.5M on share buybacks in fiscal year 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 191.3% from the prior year.

Capital Expenditures

$13.8M

YoY+37.2%

5Y CAGR-3.6%

10Y CAGR+5.6%

Usana Health Sciences Inc invested $13.8M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents an increase of 37.2% from the prior year.

USNA Income Statement

Metric	FY26	FY24	FY23	FY22	FY21	FY19
Revenue	$925.3M+8.3%	$854.5M-7.2%	$921.0M-7.8%	$998.6M-12.0%	$1.1B+7.0%	$1.1B
Cost of Revenue	$200.9M+24.6%	$161.2M-8.8%	$176.7M-8.9%	$193.9M-7.3%	$209.1M+11.5%	$187.5M
Gross Profit	$724.4M+4.5%	$693.3M-6.9%	$744.3M-7.5%	$804.7M-13.1%	$925.5M+6.0%	$873.4M
R&D Expenses	$10.7M-7.6%	$11.6M+1.1%	$11.4M-1.0%	$11.6M+8.7%	$10.6M+3.6%	$10.3M
SG&A Expenses	$337.4M+28.1%	$263.3M+2.4%	$257.0M-2.0%	$262.3M+0.4%	$261.2M-2.4%	$267.7M
Operating Income	$37.4M-43.6%	$66.3M-28.7%	$93.1M-13.5%	$107.6M-39.0%	$176.5M+20.7%	$146.2M
Interest Expense	$842K+199.6%	$281K+7.3%	$262K+36.5%	$192K-62.1%	$507K+668.2%	$66K
Income Tax	$30.1M-12.4%	$34.3M-11.3%	$38.7M-1.5%	$39.3M-26.3%	$53.3M+6.6%	$50.0M
Net Income	$10.8M-74.4%	$42.0M-34.1%	$63.8M-8.0%	$69.3M-44.4%	$124.7M+24.0%	$100.5M
EPS (Diluted)	$0.58-73.5%	$2.19-33.6%	$3.30-8.1%	$3.59-38.7%	$5.86+32.9%	$4.41

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Revenue	$226.2M+5.9%	$213.7M-9.4%	$235.8M-5.5%	$249.5M+16.8%	$213.6M+6.7%	$200.2M-5.9%	$212.9M-6.6%	$227.8M
Cost of Revenue	$49.4M+1.2%	$48.8M-2.7%	$50.2M-4.3%	$52.4M+36.0%	$38.6M-1.8%	$39.3M-2.7%	$40.3M-6.4%	$43.1M
Gross Profit	$176.8M+7.2%	$164.9M-11.2%	$185.7M-5.8%	$197.1M+12.6%	$175.1M+8.8%	$161.0M-6.7%	$172.5M-6.6%	$184.7M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$78.1M-9.2%	$85.9M+4.9%	$81.9M-10.4%	$91.4M+24.7%	$73.3M+19.7%	$61.3M-4.7%	$64.3M0.0%	$64.3M
Operating Income	$3.8M+212.0%	$1.2M-92.7%	$16.7M+6.7%	$15.7M+90.9%	$8.2M-47.4%	$15.6M-12.6%	$17.8M-27.7%	$24.7M
Interest Expense	$123K+151.0%	$49K-81.1%	$259K-37.0%	$411K+218.6%	$129K+163.3%	$49K-3.9%	$51K-1.9%	$52K
Income Tax	$5.8M-31.7%	$8.5M+1.0%	$8.4M+12.4%	$7.4M+25.3%	$5.9M-25.7%	$8.0M-18.1%	$9.8M-7.6%	$10.6M
Net Income	-$1.8M+72.8%	-$6.5M-167.6%	$9.7M+2.7%	$9.4M+111.1%	$4.5M-58.0%	$10.6M+1.7%	$10.4M-36.9%	$16.5M
EPS (Diluted)	N/A	$-0.36-169.2%	$0.52+6.1%	$0.49	N/A	$0.56+3.7%	$0.54-37.2%	$0.86

USNA Balance Sheet

Metric	FY26	FY24	FY23	FY22	FY21	FY19
Total Assets	N/A	$748.2M+18.2%	$632.8M+6.1%	$596.5M+2.1%	$584.5M+13.1%	$516.9M
Current Assets	N/A	$279.2M-33.2%	$417.7M+8.7%	$384.4M+3.0%	$373.2M+13.3%	$329.3M
Cash & Equivalents	N/A	$181.8M-45.0%	$330.4M+14.6%	$288.4M+12.2%	$257.0M+9.4%	$234.8M
Inventory	N/A	$69.7M+13.5%	$61.5M-8.4%	$67.1M-23.5%	$87.6M+27.2%	$68.9M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	$144.2M+743.0%	$17.1M-1.5%	$17.4M+0.3%	$17.3M+4.1%	$16.6M
Total Liabilities	N/A	$161.9M+19.4%	$135.6M-16.4%	$162.1M-10.8%	$181.7M+10.0%	$165.2M
Current Liabilities	N/A	$139.6M+17.5%	$118.8M-17.4%	$143.8M-5.0%	$151.5M+11.3%	$136.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$532.1M+7.0%	$497.2M+14.4%	$434.5M+7.9%	$402.8M+14.5%	$351.7M
Retained Earnings	N/A	$478.9M+7.6%	$445.2M+13.7%	$391.6M+10.9%	$353.2M+15.4%	$306.1M

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Total Assets	$742.9M+2.2%	$726.6M-1.1%	$734.5M-1.6%	$746.6M-0.2%	$748.2M+11.5%	$671.3M+6.3%	$631.4M+0.3%	$629.3M
Current Assets	$288.4M+9.2%	$264.1M+0.8%	$261.9M-6.9%	$281.4M+0.8%	$279.2M-38.1%	$451.2M+7.7%	$419.1M-0.5%	$421.1M
Cash & Equivalents	$158.4M+9.0%	$145.3M-4.0%	$151.3M-15.7%	$179.6M-1.2%	$181.8M-50.2%	$364.9M+9.8%	$332.4M+1.2%	$328.3M
Inventory	$102.6M+13.0%	$90.8M+9.0%	$83.3M+13.2%	$73.6M+5.5%	$69.7M+9.0%	$64.0M+3.5%	$61.8M+1.6%	$60.9M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$138.0M-4.4%	$144.3M0.0%	$144.2M0.0%	$144.2M0.0%	$144.2M+738.4%	$17.2M+2.1%	$16.8M-0.4%	$16.9M
Total Liabilities	$156.6M+8.0%	$145.0M-2.6%	$149.0M-8.5%	$162.7M+0.5%	$161.9M+17.1%	$138.2M+15.9%	$119.2M-7.8%	$129.3M
Current Liabilities	$128.6M+8.3%	$118.7M-2.4%	$121.6M-11.5%	$137.4M-1.6%	$139.6M+21.6%	$114.8M+10.5%	$103.9M-7.8%	$112.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$533.1M+1.0%	$528.1M-0.6%	$531.1M+0.2%	$529.8M-0.4%	$532.1M-0.2%	$533.1M+4.1%	$512.2M+2.4%	$500.0M
Retained Earnings	$465.7M-0.4%	$467.5M-1.4%	$474.0M-0.8%	$477.6M-0.3%	$478.9M+0.9%	$474.5M+2.3%	$463.9M+2.3%	$453.5M

USNA Cash Flow Statement

Metric	FY26	FY24	FY23	FY22	FY21	FY19
Operating Cash Flow	$22.3M-63.4%	$61.0M-13.7%	$70.6M-32.0%	$103.9M-35.2%	$160.4M+26.6%	$126.7M
Capital Expenditures	$13.8M+37.2%	$10.1M-30.5%	$14.5M+39.4%	$10.4M-31.1%	$15.1M-8.9%	$16.6M
Free Cash Flow	$8.5M-83.3%	$50.9M-9.3%	$56.1M-40.0%	$93.5M-35.7%	$145.3M+31.9%	$110.2M
Investing Cash Flow	-$10.1M+95.2%	-$213.1M-1679.5%	-$12.0M+3.2%	-$12.4M+63.6%	-$34.0M-171.5%	$47.5M
Financing Cash Flow	-$40.6M-525.0%	$9.6M+167.1%	-$14.2M+52.7%	-$30.1M+49.4%	-$59.4M+60.9%	-$152.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$27.5M+191.3%	$9.4M-18.6%	$11.6M-54.3%	$25.4M-55.5%	$57.0M-62.0%	$150.0M

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Operating Cash Flow	-$3.4M-72.9%	-$2.0M-116.1%	$12.2M-21.1%	$15.5M+167.6%	$5.8M-80.4%	$29.5M+269.6%	$8.0M-54.8%	$17.7M
Capital Expenditures	$2.8M-12.6%	$3.2M-36.4%	$5.0M+79.3%	$2.8M+55.5%	$1.8M-24.9%	$2.4M-10.2%	$2.7M-16.6%	$3.2M
Free Cash Flow	-$6.2M-19.9%	-$5.2M-171.7%	$7.2M-43.3%	$12.7M+218.3%	$4.0M-85.3%	$27.1M+410.2%	$5.3M-63.3%	$14.5M
Investing Cash Flow	$1.1M+134.7%	-$3.2M+23.2%	-$4.2M-7.4%	-$3.9M+98.1%	-$205.1M-8674.1%	-$2.3M-51.2%	-$1.5M+62.0%	-$4.1M
Financing Cash Flow	$13.5M+1474.2%	-$979K+97.5%	-$38.6M-166.9%	-$14.5M-163.1%	$22.9M+29497.4%	-$78K+94.2%	-$1.4M+88.7%	-$11.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	$0-100.0%	$15.2M+23.6%	$12.3M	$0	$0	$0-100.0%	$9.4M

USNA Financial Ratios

Metric	FY26	FY24	FY23	FY22	FY21	FY19
Gross Margin	78.3%-2.8pp	81.1%+0.3pp	80.8%+0.2pp	80.6%-1.0pp	81.6%-0.8pp	82.3%
Operating Margin	4.0%-3.7pp	7.8%-2.3pp	10.1%-0.7pp	10.8%-4.8pp	15.6%+1.8pp	13.8%
Net Margin	1.2%-3.8pp	4.9%-2.0pp	6.9%-0.0pp	6.9%-4.0pp	11.0%+1.5pp	9.5%
Return on Equity	N/A	7.9%-4.9pp	12.8%-3.1pp	16.0%-15.0pp	30.9%+2.4pp	28.6%
Return on Assets	N/A	5.6%-4.5pp	10.1%-1.6pp	11.6%-9.7pp	21.3%+1.9pp	19.4%
Current Ratio	N/A	2.00-1.5	3.52+0.8	2.67+0.2	2.46+0.0	2.42
Debt-to-Equity	N/A	0.30+0.0	0.27-0.1	0.37-0.1	0.45-0.0	0.47
FCF Margin	0.9%-5.0pp	6.0%-0.1pp	6.1%-3.3pp	9.4%-3.4pp	12.8%+2.4pp	10.4%

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Gross Margin	78.2%+1.0pp	77.1%-1.6pp	78.7%-0.3pp	79.0%-3.0pp	82.0%+1.6pp	80.4%-0.7pp	81.0%-0.0pp	81.1%
Operating Margin	1.7%+1.1pp	0.6%-6.5pp	7.1%+0.8pp	6.3%+2.4pp	3.8%-4.0pp	7.8%-0.6pp	8.4%-2.4pp	10.8%
Net Margin	-0.8%+2.3pp	-3.0%-7.1pp	4.1%+0.3pp	3.8%+1.7pp	2.1%-3.2pp	5.3%+0.4pp	4.9%-2.4pp	7.3%
Return on Equity	-0.3%+0.9pp	-1.2%-3.1pp	1.8%+0.1pp	1.8%+0.9pp	0.8%-1.2pp	2.0%-0.1pp	2.0%-1.3pp	3.3%
Return on Assets	-0.2%+0.7pp	-0.9%-2.2pp	1.3%+0.1pp	1.3%+0.7pp	0.6%-1.0pp	1.6%-0.1pp	1.7%-1.0pp	2.6%
Current Ratio	2.24+0.0	2.23+0.1	2.15+0.1	2.05+0.0	2.00-1.9	3.93-0.1	4.03+0.3	3.74
Debt-to-Equity	0.29+0.0	0.270.0	0.28-0.0	0.310.0	0.30+0.0	0.26+0.0	0.23-0.0	0.26
FCF Margin	-2.7%-0.3pp	-2.4%-5.5pp	3.0%-2.0pp	5.1%+3.2pp	1.9%-11.7pp	13.6%+11.1pp	2.5%-3.9pp	6.4%

Similar Companies

Oatly Group Ab OTLY

$318.5M

WESTROCK COFFEE CO WEST

$413.7M

Lifeway Food LWAY

$344.2M

Seneca Foods Corp SENEB

$1.0B

John B. Sanfilippo & Son JBSS

$964.6M

Frequently Asked Questions

What is Usana Health Sciences Inc's annual revenue?

Usana Health Sciences Inc (USNA) reported $925.3M in total revenue for fiscal year 2026. This represents a 8.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Usana Health Sciences Inc's revenue growing?

Usana Health Sciences Inc (USNA) revenue grew by 8.3% year-over-year, from $854.5M to $925.3M in fiscal year 2026.

Is Usana Health Sciences Inc profitable?

Yes, Usana Health Sciences Inc (USNA) reported a net income of $10.8M in fiscal year 2026, with a net profit margin of 1.2%.

What is Usana Health Sciences Inc's EBITDA?

Usana Health Sciences Inc (USNA) had EBITDA of $70.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Usana Health Sciences Inc's gross margin?

Usana Health Sciences Inc (USNA) had a gross margin of 78.3% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Usana Health Sciences Inc's operating margin?

Usana Health Sciences Inc (USNA) had an operating margin of 4.0% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Usana Health Sciences Inc's net profit margin?

Usana Health Sciences Inc (USNA) had a net profit margin of 1.2% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Usana Health Sciences Inc's free cash flow?

Usana Health Sciences Inc (USNA) generated $8.5M in free cash flow during fiscal year 2026. This represents a -83.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Usana Health Sciences Inc's operating cash flow?

Usana Health Sciences Inc (USNA) generated $22.3M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Usana Health Sciences Inc's capital expenditures?

Usana Health Sciences Inc (USNA) invested $13.8M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Usana Health Sciences Inc spend on research and development?

Usana Health Sciences Inc (USNA) invested $10.7M in research and development during fiscal year 2026.

Does Usana Health Sciences Inc buy back shares?

Yes, Usana Health Sciences Inc (USNA) spent $27.5M on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

How many shares does Usana Health Sciences Inc have outstanding?

Usana Health Sciences Inc (USNA) had 18M shares outstanding as of fiscal year 2026.

Are Usana Health Sciences Inc's earnings high quality?

Usana Health Sciences Inc (USNA) has an earnings quality ratio of 2.08x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Usana Health Sciences Inc cover its interest payments?

Usana Health Sciences Inc (USNA) has an interest coverage ratio of 44.5x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.